恢复期血浆治疗住院COVID-19患者的开放标签随机对照试验
这项开放标签随机对照试验将940例住院COVID-19患者按2:1分配至恢复期血浆组或标准治疗组,主要终点为30天内插管或死亡。因无效性提前终止,恢复期血浆未降低插管或死亡风险(RR=1.16,95%CI 0.94-1.43,P=0.18),但严重不良事件更多,且抗体特征可调节疗效。
要点
- 恢复期血浆未降低住院COVID-19患者30天插管或死亡风险。
- 恢复期血浆组严重不良事件发生率更高(33.4% vs 26.4%)。
- 中和抗体和ADCC活性越高,血浆潜在危害效应越低。
核心结论
- 恢复期血浆未降低住院COVID-19患者30天内插管或死亡风险。
- 输注抗体特征不利的恢复期血浆可能与更差临床结局相关。
研究设计与样本
- 开放标签随机对照试验,成人COVID-19需氧治疗且呼吸症状起病12天内。
- 按2:1分配至500 ml恢复期血浆组或标准治疗组。
- 940例随机,921例纳入意向性治疗分析。
- 因无效性提前终止于计划入组的78%。
主要发现
- 主要终点插管或死亡:血浆组199/614(32.4%),标准治疗组86/307(28.0%),RR=1.16(95%CI 0.94-1.43,P=0.18)。
- 严重不良事件:血浆组33.4%,标准治疗组26.4%,RR=1.27(95%CI 1.02-1.57,P=0.034)。
- 中和抗体每标准化log增加独立降低血浆潜在危害效应(OR=0.74,95%CI 0.57-0.95)。
- ADCC每标准化log增加独立降低血浆潜在危害效应(OR=0.66,95%CI 0.50-0.87)。
- 全长跨膜刺突蛋白IgG增加血浆潜在危害效应(OR=1.53,95%CI 1.14-2.05)。
临床怎么用
- 不推荐对住院COVID-19患者常规使用恢复期血浆。
- 若考虑使用,需关注血浆抗体特征,避免输注抗体谱不利的血浆。
局限性
- 开放标签设计。
- 因无效性提前终止,样本量未达计划入组。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The efficacy of convalescent plasma for coronavirus disease 2019 (COVID-19) is unclear. Although most randomized controlled trials have shown negative results, uncontrolled studies have suggested that the antibody content could influence patient outcomes. We conducted an open-label, randomized controlled trial of convalescent plasma for adults with COVID-19 receiving oxygen within 12 d of respiratory symptom onset ( NCT04348656 ). Patients were allocated 2:1 to 500 ml of convalescent plasma or standard of care. The composite primary outcome was intubation or death by 30 d. Exploratory analyses of the effect of convalescent plasma antibodies on the primary outcome was assessed by logistic regression. The trial was terminated at 78% of planned enrollment after meeting stopping criteria for futility. In total, 940 patients were randomized, and 921 patients were included in the intention-to-treat analysis. Intubation or death occurred in 199/614 (32.4%) patients in the convalescent plasma arm and 86/307 (28.0%) patients in the standard of care arm-relative risk (RR) = 1.16 (95% confidence interval (CI) 0.94-1.43, P = 0.18). Patients in the convalescent plasma arm had more serious adverse events (33.4% versus 26.4%; RR = 1.27, 95% CI 1.02-1.57, P = 0.034). The antibody content significantly modulated the therapeutic effect of convalescent plasma. In multivariate analysis, each standardized log increase in neutralization or antibody-dependent cellular cytotoxicity independently reduced the potential harmful effect of plasma (odds ratio (OR) = 0.74, 95% CI 0.57-0.95 and OR = 0.66, 95% CI 0.50-0.87, respectively), whereas IgG against the full transmembrane spike protein increased it (OR = 1.53, 95% CI 1.14-2.05). Convalescent plasma did not reduce the risk of intubation or death at 30 d in hospitalized patients with COVID-19. Transfusion of convalescent plasma with unfavorable antibody profiles could be associated with worse clinical outcomes compared to standard care.
引用
- Bégin P, Callum J, Jamula E, et al. Convalescent plasma for hospitalized patients with COVID-19: an open-label, randomized controlled trial. Nat Med. 2021. PMID: 34504336. doi:10.1038/s41591-021-01488-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。